[go: up one dir, main page]

TR200000175T2 - Endogenik gen aktivasyonu ile eritropoietinin hazırlanması. - Google Patents

Endogenik gen aktivasyonu ile eritropoietinin hazırlanması.

Info

Publication number
TR200000175T2
TR200000175T2 TR2000/00175T TR200000175T TR200000175T2 TR 200000175 T2 TR200000175 T2 TR 200000175T2 TR 2000/00175 T TR2000/00175 T TR 2000/00175T TR 200000175 T TR200000175 T TR 200000175T TR 200000175 T2 TR200000175 T2 TR 200000175T2
Authority
TR
Turkey
Prior art keywords
epo
human
erythropoietin
preparation
gene activation
Prior art date
Application number
TR2000/00175T
Other languages
English (en)
Inventor
Stern Anne
Brandt Michael
Honold Konrad
Auer Johannes
Koll Hans
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000175(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1997153681 external-priority patent/DE19753681A1/de
Priority claimed from US09/113,692 external-priority patent/US6548296B1/en
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of TR200000175T2 publication Critical patent/TR200000175T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Bulus, endogen insan eritropoietin genin aktivasyonundan ötürü, insan EPO'sunun bir farmasötik preparasyon halinde ekonomik biçimde üretilmesine olanak saglamak üzere eritropoietini (EPO) yeterli miktarlar ve yeterli saflik derecesinde üretebilen insan hücrelerine dairdir. Bulus, ayni zamanda, bu tür insan EPO-üretici hücrelerinin üretilmesi için bir isleme, insan hücreleri içinde endogen EPO geninin aktive edilmesi için DNA-konstruktlari ve EPO' nun insan hücrelerinde büyük ölçekte üretimi için bir isleme de dairdir.
TR2000/00175T 1997-07-23 1998-07-22 Endogenik gen aktivasyonu ile eritropoietinin hazırlanması. TR200000175T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97112640 1997-07-23
DE1997153681 DE19753681A1 (de) 1997-12-03 1997-12-03 Erythropoietin mit hoher spezifischer Aktivität
US09/113,692 US6548296B1 (en) 1997-07-23 1998-07-10 Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof

Publications (1)

Publication Number Publication Date
TR200000175T2 true TR200000175T2 (tr) 2001-01-22

Family

ID=27217987

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00175T TR200000175T2 (tr) 1997-07-23 1998-07-22 Endogenik gen aktivasyonu ile eritropoietinin hazırlanması.

Country Status (13)

Country Link
EP (1) EP0986644B1 (tr)
JP (1) JP4541539B2 (tr)
CN (1) CN1151258C (tr)
AT (1) ATE341625T1 (tr)
AU (1) AU754619B2 (tr)
BR (1) BRPI9811031B8 (tr)
CA (1) CA2298015C (tr)
DE (1) DE59813758D1 (tr)
DK (1) DK0986644T3 (tr)
ES (1) ES2273434T3 (tr)
TR (1) TR200000175T2 (tr)
TW (1) TW574372B (tr)
WO (1) WO1999005268A1 (tr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
CN1280309C (zh) 1997-12-03 2006-10-18 罗切诊断学有限公司 具有高比活的促红细胞生成素
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
CA2437333A1 (en) 2001-02-02 2002-08-22 Ortho-Mcneil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
KR100493703B1 (ko) * 2001-10-30 2005-06-02 신풍제약주식회사 동물세포용 재조합 벡터 및 에리트로포이에틴을 대량으로 생산하기 위한 동물세포용 발현벡터
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
WO2003045423A1 (en) 2001-11-28 2003-06-05 Ortho-Mcneil Pharmaceutical, Inc. Erythropoietin dosing regimen for treating anemia
JP4480398B2 (ja) 2001-12-07 2010-06-16 クルセル ホランド ベー ヴェー ウイルス、ウイルス分離株及びワクチンの製造方法
AU2003218045A1 (en) 2002-03-11 2003-09-29 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
PT2287288E (pt) 2002-07-09 2012-12-10 Baxter Int Meio isento de proteína animal para cultura de células
ATE414144T1 (de) 2003-05-09 2008-11-15 Crucell Holland Bv Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2007077217A2 (en) 2006-01-04 2007-07-12 Baxter International Inc. Oligopeptide-free cell culture media
CN101062407A (zh) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
US20110091474A1 (en) * 2007-03-12 2011-04-21 Kang Zhang Compositions and Methods For Diagnosing and Treating Diabetic Micro Vascular Complications
NZ620606A (en) 2008-02-08 2015-08-28 Ambrx Inc Modified leptin polypeptides and their uses
WO2010034442A1 (en) 2008-09-23 2010-04-01 F. Hoffmann-La Roche Ag Purification of erythropoietin
CN102232085A (zh) 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
CN102659928B (zh) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用
CN102659927B (zh) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用
CN104059128B (zh) * 2010-09-17 2016-08-03 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
JPS62171696A (ja) * 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd ヒトエリスロポエチンの製造方法
JPS62265992A (ja) * 1986-05-12 1987-11-18 Ajinomoto Co Inc ヒト細胞を用いる有用物質の製造方法
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
JPH01165393A (ja) * 1987-12-21 1989-06-29 Sumitomo Chem Co Ltd 組換えヒトエリスロポエチンの精製方法
SG122763A1 (en) * 1989-11-06 2006-06-29 Cell Genesys Inc Production of proteins using homologous recombination
EP0505500B1 (en) * 1989-12-22 1997-07-30 Applied Research Systems Ars Holding N.V. Endogenous gene expression modification with regulatory element by way of homologous recombination
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof

Also Published As

Publication number Publication date
JP2001511343A (ja) 2001-08-14
EP0986644A1 (de) 2000-03-22
BRPI9811031A (pt) 2000-08-08
AU754619B2 (en) 2002-11-21
CA2298015A1 (en) 1999-02-04
BRPI9811031B8 (pt) 2021-07-06
TW574372B (en) 2004-02-01
DE59813758D1 (de) 2006-11-16
ES2273434T3 (es) 2007-05-01
JP4541539B2 (ja) 2010-09-08
CA2298015C (en) 2015-01-27
ATE341625T1 (de) 2006-10-15
WO1999005268A1 (de) 1999-02-04
CN1265143A (zh) 2000-08-30
BRPI9811031B1 (pt) 2011-10-04
DK0986644T3 (da) 2007-01-29
CN1151258C (zh) 2004-05-26
EP0986644B1 (de) 2006-10-04
AU8978698A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
TR200000175T2 (tr) Endogenik gen aktivasyonu ile eritropoietinin hazırlanması.
WO2002029083A3 (en) Industrial-scale serum-free production of recombinant proteins in mammalian cells
BR0010806A (pt) Métodos e materiais para a sìntese de produtos orgânicos
ATE348145T1 (de) Hefevarianten und verfahren zur herstellung von glykoprotein enthaltenden zuckerketten vom säugetiertyp
AU2270899A (en) Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments
DE69633669D1 (de) Verfahren zur zelltransfektion mit liposomal-verkapselten nukleinsäuren
HUP9801697A2 (hu) Új protein és eljárás előállítására
AU7471698A (en) Intracellular production of hepatitis c e1 and e2 truncated polypeptides
WO2002101006A3 (en) Production of proteins in plants
AU5102899A (en) Process and materials for production of glucosamine
ATE314389T1 (de) Verkürzter aus einer gliazelllinie gewonnener neurotropher faktor
AU1159400A (en) Substituted 4-amino-2-aryl-cyclopenta(D)pyrimidines, their production and use and pharmaceuticalreparations containing same
BR0115036A (pt) Processo para a preparação de um composto
CA2312943A1 (en) Constitutive expression of non-infectious hiv-like particles
ATE128187T1 (de) Herstellung von aminosäuren durch methylotrophe bazillen.
NZ325259A (en) Phospholipid derivatives of phosphono-carboxylic acids, the production of said derivatives and the use of said derivatives as antiviral medicaments
EP0869128A3 (en) Process for the production of octaphenylcyclotetrasiloxane and sym-tetramethyltetraphenyl cyclotetrasiloxane
GR3017577T3 (en) New anticancer antibiotic substance, the production and uses thereof.
PL348509A1 (en) Production of ascorbic acid using yeast
HUT63458A (en) Process for producing and using polypeptides participating in the biosynthesis of cobalamins and/or cobamides and dna sequences encoding them
CA2191407A1 (en) Process for using the yeast adh ii promoter system for the biotechnological production of heterologous proteins in high yields
ES2058047T3 (es) Resolucion de acido arilalcanoico.
ATE256664T1 (de) Herstellung von (s)-decahydroisochinolin-3- carbonsäure-t-butylamid
DE69939876D1 (de) Methoden zur massenkultivierung von zellen die rekombinantes menschliches erythropoietin produzieren
AU2725399A (en) Substituted isoindolones and their use as cyclic gmp modulators in medicaments